ライフサイエンスコーパス: actinic

1 , cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it i

2 ges corresponding to an increasing burden of actinic damage and CSCC, was used to guide survey design

3 A novel actinic damage and skin cancer index (AD-SCI), consistin

4 Actinic damage and squamous atypia were found in grafts

5 posure instrument and histologic evidence of actinic damage in a population-based study of keratinocy

6 ls aged 60 years and older with considerable actinic damage were enrolled in a prospective randomized

7 radiation and therefore develop accelerated actinic damage, including cancer, on sun-exposed tissue.

8 Although effective in treating actinic damage, topical photodynamic therapy (PDT) has b

9 e exposure related to histologic evidence of actinic damage.

10 Chronic actinic dermatitis (CAD) is classically described in old

11 Chronic actinic dermatitis presents with an earlier age at onset

12 iant cells associated with a focus of severe actinic elastosis.

13 The primary donor recovery kinetics after an actinic flash revealed a pronounced dependence on the ti

14 hange in absorbance at 478 nm after a single actinic flash was delivered to the sample.

15 lengthy preillumination of a sample and the actinic flash.

16 These states were detected both by short actinic flashes and by the switching of the actinic illu

17 pyruvic acid through the absorption of solar actinic flux generates methylhydroxycarbene (MHC) in the

18 n cool Earth's surface, they also change the actinic flux of ultraviolet (UV) radiation.

19 B <-- X spectrum is combined with the solar actinic flux to estimate an atmospheric lifetime for CH(

20 ctive gases from the ocean surface, and high actinic fluxes in a broken cloud field.

21 Conjunctival actinic granuloma has diverse clinical and histopatholog

22 Conjunctival actinic granuloma is an underrecognized entity.

23 Diagnosis of actinic granuloma of the conjunctiva was confirmed.

24 This led to the final diagnoses of actinic granuloma of the conjunctiva.

25 Histopathologically, actinic granuloma was associated with pterygium (n = 6,

26 were searched for all cases of conjunctival actinic granuloma.

27 ), but were diagnosed histopathologically as actinic granuloma.

28 -type bacteriorhodopsin photocycle formed by actinic illumination at 230 K has been determined by x-r

29 vailability of inorganic carbon, and various actinic illumination conditions.

30 actinic flashes and by the switching of the actinic illumination level between different stationary

31 thylakoid PMF is actually present long after actinic illumination of the thylakoids ceases and that t

32 PMF decays rapidly after the termination of actinic illumination, and it has been well established v

33 orescence yield following brief cessation of actinic illumination, or F(m)", is not.

34 uorescence yield observed under steady-state actinic illumination, or F(m)', has been shown to be pro

35 conditions and in air (21 percent O2) at an actinic intensity of 200 microeinsteins per square meter

36 This was achieved by applying actinic irradiance perpendicular to one side of thallus

37 nd/or overestimations, depending on incident actinic irradiance.

38 Actinic keratoses (AK) are common premalignant skin lesi

39 Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two

40 ar test for identifying transformation-prone actinic keratoses (AKs) and aggressive squamous cell car

41 sed human skin and subsequent development of actinic keratoses (AKs) and skin cancers.

42 Actinic keratoses (AKs) are lesions of epidermal keratin

43 e, risk factors, and longitudinal outlook of actinic keratoses (AKs) are limited.

44 Actinic keratoses (AKs) are small scaly red areas of ski

45 ed to be effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no rando

46 The presence of actinic keratoses (AKs) increases a patient's risk of de

47 pical methyl 5-aminolevulinic acid (MAL) for actinic keratoses (AKs) is as effective as conventional

48 osmetically favorable treatment modality for actinic keratoses (AKs).

49 SCCs (n = 11) than in cSCC in situ (n = 69), actinic keratoses (n = 63), and normal skin (n = 5).

50 The percentage of reduction in the number of actinic keratoses (primary outcome), local skin reaction

51 squamous-cell and basal-cell carcinomas) and actinic keratoses among high-risk immunocompetent patien

52 At 3-monthly visits, new actinic keratoses and basal-cell carcinomas were identif

53 ilar mutations are seen in later precancers (actinic keratoses and Bowen's disease).

54 egories: intraepithelial carcinoma including actinic keratoses and Bowen's disease; basal cell carcin

55 Actinic keratoses and cutaneous squamous cell carcinomas

56 n of C1r and C1s was lower in cSCCs in situ, actinic keratoses and in normal skin.

57 veness of promoting sunscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

58 rom noncancerous skin abnormalities, such as actinic keratoses and seborrheic keratoses, achieving 92

59 s of the mutant p53 clusters associated with actinic keratoses and squamous cell carcinomas.

60 Treating actinic keratoses and the surrounding skin area (i.e., f

61 ting a CD4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin

62 Surprisingly, actinic keratoses are often not related to their neighbo

63 Actinic keratoses arose in 9% of grafts treated with ult

64 itu SCCs in the 5 years prior to enrollment, actinic keratoses count at enrollment, a history of ever

65 ia verruciformis keratosis and in some cases actinic keratoses demonstrated similar histology associa

66 and basal-cell carcinomas and the number of actinic keratoses during the 12-month intervention perio

67 prevalence of untreated skin malignancy and actinic keratoses in high-risk kidney and liver transpla

68 he rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.

69 to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transp

70 versus 26.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001).

71 Actinic keratoses on the face and ears were counted by s

72 studies, we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk o

73 ndomly assigned, in a 1:1 ratio, adults with actinic keratoses on the face or scalp to receive either

74 i67 positive cells, unlike the situation for actinic keratoses or basal cell carcinomas.

75 therapy for 2 or 3 consecutive days to treat actinic keratoses produced clinically relevant sustained

76 Mutational profiling of cSCCs adjacent to actinic keratoses reveals TERT promoter and CDKN2A mutat

77 a promising option to evaluate emerging new actinic keratoses therapies.

78 Dermatologists treat actinic keratoses to prevent non-melanoma skin cancer.

79 12-month intervention period, the number of actinic keratoses until 6 months after randomization, sa

80 The number of actinic keratoses was 11% lower in the nicotinamide grou

81 The annualised rate of new actinic keratoses was 8.2 among the patients assigned T4

82 ell carcinoma and basal cell carcinoma), and actinic keratoses was compared between vitiligo cases an

83 protective measures, other skin cancers, and actinic keratoses were not.

84 c therapy (PDT) is used extensively to treat actinic keratoses(AKs).

85 and 5 of 11 patients [45.5%] diagnosed with actinic keratoses).

86 Actinic keratoses, a precancerous benign skin growth and

87 rform multi-omic profiling of keratinocytes, actinic keratoses, and cSCCs.

88 cinomas, five squamous cell carcinomas, five actinic keratoses, and one case of Bowen's disease) and

89 l cell carcinomas, squamous cell carcinomas, actinic keratoses, atypical nevi, melanocytic nevi, blue

90 hat both methods are viable ways to evaluate actinic keratoses, even when the investigators differ at

91 , scaly plaques, and large tumors resembling actinic keratoses, SCC in situ, and SCCs, respectively.

92 associated cSCCs compared with cSCC in situ, actinic keratoses, seborrheic keratoses, and normal skin

93 all and those for presumptive skin cancer or actinic keratoses, skin biopsies, or PCP diagnostic accu

94 ne, previous skin cancer excisions, previous actinic keratoses, smoking status, and height) and 2 sta

95 gonist approved for the topical treatment of actinic keratoses, superficial basal cell carcinoma, and

96 nic NRF2 target genes were activated in some actinic keratoses, the major precancerous lesion in huma

97 gnificantly younger, had more nevi but fewer actinic keratoses, were more likely to report a family h

98 TERT promoter and CDKN2A mutations emerge in actinic keratoses, whereas additional mutations that ina

99 ociated with premalignant lesions resembling actinic keratoses, whereas those in the heterozygous and

100 Cs and their premalignant precursor lesions, actinic keratoses.

101 o 3 days is effective for field treatment of actinic keratoses.

102 rapy) can eradicate clinical and subclinical actinic keratoses.

103 CC) as well as dysplastic precursor lesions, actinic keratoses.

104 ture abnormalities, pigment dyschromias, and actinic keratoses.

105 ent, with approximately 30% having 5 or more actinic keratoses.

106 ar lentigines or seborrheic keratoses, and 3 actinic keratoses.

107 n and to reduce the rate of new premalignant actinic keratoses.

108 proteins in human skin SCC and precancerous actinic keratoses.

109 l diagnosis, followed by pterygium (36%) and actinic keratosis (19%).

110 There was no significant association for actinic keratosis (aHR = 0.88, 95% CI = 0.77-1.01).

111 Treatment of actinic keratosis (AK) aims to prevent cutaneous squamou

112 Accurate differentiation between actinic keratosis (AK) and cutaneous squamous cell carci

113 IGF-1 levels, can prevent the occurrence of actinic keratosis (AK) and NMSC.METHODSA human skin/immu

114 Actinic keratosis (AK) are precancerous lesions of the s

115 cell carcinoma (cSCC) after the diagnosis of actinic keratosis (AK) has not been studied during long

116 Actinic keratosis (AK) is a skin growth induced by UV li

117 dity and socioeconomic costs associated with actinic keratosis (AK) management represent major public

118 (mean time, 6 months [range, 0-18 months]), actinic keratosis (AK) of the same sun-exposed skin area

119 ase progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous s

120 anced malignancies, ranging from a precursor actinic keratosis (AK) to squamous cell carcinoma (SCC)

121 Benefit and harm associated with treating actinic keratosis (AK) with the immune response modifier

122 Actinic keratosis (AK), a skin growth induced by ultravi

123 Actinic Keratosis (AK), Intraepidermal Carcinoma (IEC),

124 rventions are available for the treatment of actinic keratosis (AK).

125 ion with a distinct precancerous lesion, the actinic keratosis (AK).

126 ude the following: cryotherapy for scattered actinic keratosis (AK); field therapy for AK when groupe

127 , squamous cell carcinoma (SCC; n = 28), and actinic keratosis [AK (a precursor to SCC); n = 38].

128 Lastly, we evaluated the Raman signal in actinic keratosis and basal cell carcinoma lesions and p

129 te' stages of epidermal carcinogenesis; late actinic keratosis and cSCC.

130 duction in PTEN levels in human premalignant actinic keratosis and malignant SCCs, supporting a key r

131 esolution analysis of shotgun metagenomes of actinic keratosis and SCC in healthy skin, revealing the

132 g the microbial community shifts specific to actinic keratosis and SCC.

133 riasis and show promise for the treatment of actinic keratosis and squamous cell carcinoma.

134 at TRAF1 expression is up-regulated in human actinic keratosis and squamous cell carcinoma.

135 was superior to vehicle for the treatment of actinic keratosis at 2 months but was associated with tr

136 in vivo, as compared with cSCC in situ, and actinic keratosis by RNA in situ hybridization; and the

137 uamous cell carcinoma (SCC) and premalignant actinic keratosis compared with that in healthy skin to

138 uamous-cell and basal-cell carcinoma counts, actinic keratosis counts, or quality-of-life scores were

139 erved in any cancer-related end points or in actinic keratosis counts.

140 aseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-blind clinical

141 age, history of skin cancer, and history of actinic keratosis in both data sets, and male sex and th

142 e the current knowledge of interventions for actinic keratosis in nonscalp and nonface localizations.

143 Actinic keratosis is a common precursor to sun-related s

144 Actinic keratosis is a precursor to cutaneous squamous c

145 Actinic keratosis is the most frequent premalignant skin

146 rds cSCC: Normal epidermis, solar elastosis, actinic keratosis KIN1-2, advanced actinic keratosis KIN

147 lastosis, actinic keratosis KIN1-2, advanced actinic keratosis KIN3 and well-differentiated cSCC.

148 a reduction of 75% or more in the number of actinic keratosis lesions from baseline to 12 months aft

149 e end of treatment in patients with multiple actinic keratosis lesions on the head, 5% fluorouracil c

150 ts with a clinical diagnosis of five or more actinic keratosis lesions on the head, involving one con

151 rventions are available for the treatment of actinic keratosis located on the face or scalp.

152 lated only in invasive SCC nests, but not in actinic keratosis or in situ SCC, compared with normal e

153 Over 80% had actinic keratosis present, with approximately 30% having

154 Evaluation of actinic keratosis therapy depends on reliable measures o

155 fined progression sequence from precancerous actinic keratosis to invasive cSCC.

156 nal microbial dysbiosis from healthy skin to actinic keratosis to SCC, supporting further investigati

157 normal epidermis, solar elastosis and early actinic keratosis to the 'late' stages of epidermal carc

158 effects have limited the efficacy of current actinic keratosis treatments.

159 ential expression of CD200 in normal skin vs actinic keratosis vs SCC in situ vs invasive SCC.

160 Actinic keratosis was the most common diagnosis associat

161 nd skin lesions resulting from sun exposure (actinic keratosis), and individual Neandertal alleles we

162 treatment of a precancerous skin condition (actinic keratosis), and phorbol derivatives such as resi

163 ogenesis--changes that resemble hyperplastic actinic keratosis, a commonly observed human precancerou

164 tate, which is approved for the treatment of actinic keratosis, a precancerous skin condition.

165 ormal skin, PTEN levels are reduced in human actinic keratosis, a precancerous skin lesion caused by

166 In human actinic keratosis, a precursor of squamous cell carcinom

167 eing investigated as a topical treatment for actinic keratosis, a precursor of squamous-cell carcinom

168 in skin biopsies from 40 healthy donors, 13 actinic keratosis, and 74 cSCC patients.

169 perproliferative diseases such as psoriasis, actinic keratosis, and certain neoplasias.

170 5% hyaluronan inhibits basal cell carcinoma, actinic keratosis, and murine colon-26 growth in vivo.

171 trials for eradicating basal cell carcinoma, actinic keratosis, and squamous cell carcinoma (SCC) in

172 approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.

173 oid concentrations in basal cell carcinomas, actinic keratosis, and their perilesional skin demonstra

174 Sun-induced skin lesions, in particular actinic keratosis, are generally considered as premalign

175 ike Melanocytic nevus, Basal cell carcinoma, Actinic Keratosis, Benign keratosis, Dermatofibroma, Vas

176 uppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in

177 nd safety of a new topical field therapy for actinic keratosis, ingenol mebutate gel (0.015% for face

178 sal cell carcinoma, squamous cell carcinoma, actinic keratosis, melanocytic nevi, angiokeratoma, derm

179 were thought clinically to be pingueculitis, actinic keratosis, or ocular surface squamous neoplasia

180 d included the search terms solar keratosis, actinic keratosis, photodynamic therapy, and photochemot

181 n hyperproliferative skin diseases including actinic keratosis, squamous and basal cell carcinoma as

182 -fluorouracil (5-FU) as an immunotherapy for actinic keratosis.

183 ms data for outpatient encounters related to actinic keratosis.

184 rmine the effects of tirbanibulin therapy on actinic keratosis.

185 skin defects characteristic of psoriatic and actinic keratosis.

186 treatment of the precancerous skin condition actinic keratosis.

187 *-) radicals ( approximately 5 mus after the actinic laser flash) the transient absorbance of neutral

188 With increasing actinic laser strength, the M-fast cycle at first rises

189 hose with a self-reported history of treated actinic lesions (group 2), and those without either (gro

190 melanoma (group 1; n = 1433) and/or treated actinic lesions (group 2; n = 24,006) were more likely t

191 ctors (sunburns, history of skin cancers and actinic lesions), and polygenic risk scores for melanoma

192 lly controlled, spatially separated beams of actinic light and a fluorescence imaging system.

193 sses that occur upon rapid shuttering of the actinic light are analyzed.

194 l crystals were trapped by illuminating with actinic light at 230 K, followed by quenching in liquid

195 e (PM) to dilute Triton X-100 eliminates the actinic light effect on the relative amounts of fast M (

196 PAM fluorescence parameters under a range of actinic light intensities (steady-state fluorescence yie

197 ng the same sample to a sequence of distinct actinic light intensities.

198 s fixed) with induction/relaxation kinetics (actinic light intensity is fixed and the response is fol

199 sample by combining the measurement of LCs (actinic light intensity is varied while measuring time i

200 rties of the photocycle caused by changes in actinic light intensity.

201 ifteen-day-old cultures were exposed to blue actinic light or to white fluorescent light for 24 hours

202 n chlorophyll fluorescence after turning off actinic light reflects nonphotochemical reduction of the

203 n of a whole LC, including a large number of actinic light steps and adequate replication, within the

204 as possible explanations for the ability of actinic light to modify the kinetics and pathways of the

205 suggest that this perceptive site gives the actinic light which has traveled downward through the le

206 ht response curves measured under controlled actinic light with the same leaves.

207 ld, (2) the mole fraction of M-fast (at high actinic light) decreased from 50 to 20%, and (3) the tim

208 , biosensor film thickness, intensity of the actinic light, illumination cycle, and temperature on th

209 derived from cells differentially exposed to actinic light, where cells located deeper inside tissues

210 of the BR photocycle to different levels of actinic light.

211 hyll fluorescence increase after turning off actinic light.

212 following excitation with a pulse of 477-nm actinic light.

213 easured quantum yields with even exposure to actinic light.

214 vement in multiple intact plants under white actinic light.

215 Disseminated superficial actinic porokeratosis (DSAP) is an inherited or sporadic

216 each skin lesion of disseminated superficial actinic porokeratosis originates from a postnatal kerati

217 These tumours appeared to arise earlier in actinic progression and grew more rapidly than tumours o

218 Actinic prurigo and polymorphic light eruption are two o

219 genetic background, supporting the view that actinic prurigo may represent a human leukocyte antigen-

220 ained through polymorphic light eruption and actinic prurigo probands using segregation analysis.

221 polymorphic light eruption) in relatives of actinic prurigo probands was 23.7%, with a relative risk

222 ght eruption in families ascertained through actinic prurigo probands, as evidence of a shared pathog

223 suggests that polymorphic light eruption and actinic prurigo share a common genetic background, suppo

224 No appreciable absorption in the solar actinic region (lambda > 290 nm) was observed, leaving t

225 protect the retina from damage by absorbing actinic short-wave light (analogous to internal sunglass

226 (represented by prior sunburns and signs of actinic skin damage identified by dermatologists), age,

227 ranging from <.001 to .04 when adjusted for actinic skin damage on the hands).

228 sex, age, sunburns in the past, and signs of actinic skin damage, the associations remained significa

229 g from <.001 to .01 when adjusted for dorsal actinic skin damage; and OR, 2.54 [95% CI, 1.76-3.67] fo

230 g from <.001 to .04 when adjusted for facial actinic skin damage; OR, 2.36 [95% CI, 1.62-3.43] for R/

231 and no more than five destructively treated actinic skin lesions.

232 ect seen particularly in those with previous actinic skin tumors.

233 material composition utilizing multimaterial actinic spatial control (MASC) during additive manufactu

234 d that we refer to as infusion multimaterial actinic spatial control additive manufacturing (iMASC-AM

235 Here we characterize the actinic step of DASA-photoswitching and its key intermed

236 unds that readily absorb in the tropospheric actinic window (ionic organic complexes, PAHs, aromatic